Dayclazide-Total 60
Dayclazide-Total 60
Composition- Each uncoated bilayered tablet contains:
Metformin Hydrochloride I.P. 500 mg.(in sustained release form)
Gliclazide I.P. 60 mg.(in sustained release form)
Pioglitazone Hydrochloride I.P. 15 mg.
equivalent to Pioglitazone
Quick Comparison
| Settings | Dayclazide-Total 60 remove | ROZUTION-10 remove | ROZUTION F remove | DAYCLAZIDE MP40 remove | DAYCLAZIDE - 80 remove | Azneten M Forte remove |
|---|---|---|---|---|---|---|
| Image | |  |  |  |  |  |
| SKU | ||||||
| Rating | ||||||
| Price | ||||||
| Stock | 10 in stock | 10 in stock | 10 in stock | 10 in stock | 10 in stock | 10 in stock |
| Availability | 10 in stock | 10 in stock | 10 in stock | 10 in stock | 10 in stock | 10 in stock |
| Add to cart | ||||||
| Description | Dayclazide-Total 60Composition- Each uncoated bilayered tablet contains: Metformin Hydrochloride I.P. 500 mg.(in sustained release form) Gliclazide I.P. 60 mg.(in sustained release form) Pioglitazone Hydrochloride I.P. 15 mg. equivalent to Pioglitazone | Rozution (rosuvastatin 10& 20 mg)Composition- Each film coated tablet contains rosuvastatin calcium IP eqv to rosuvastatin 10/20 mg | Rozution F (rosuvastatin 10 mg +fenofibrate 145 mg)Composition- Each film coated tablet contains rosuvastatin calcium IP eqv to rosuvastatin 10 mg and fenofibrate (micronized) IP 145 mg. | Dayclazide MP 40 & 80 mg (gliclazide 40/80mg + metformin 500mg + pioglitazone 15mg)Composition- Each uncoated bilayer tablet contains gliclazide 80mg, pioglitazone 15mg and metformin 500mg. | DAYCLAZIDE - 80 (Gliclazide 80 mg)Composition- Each uncoated tablet contains gliclazide 80 mg. | Azneten M Forte (Teneligliptin -20 mg+ Metformin- 1000 MG)Composition- Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP Equivalent to Teneligliptin 20 mg Metformin Hydrochloride IP 1000 mg (as extended release form) |
| Content | ||||||
| Weight | ||||||
| Dimensions | N/A | N/A | N/A | N/A | N/A | N/A |
| Additional information |
Reviews
There are no reviews yet.